TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine…
From humble beginnings in southern Switzerland to crossing the USD 1 billion revenue mark, IBSA has quietly redefined what it means to grow a pharmaceutical company, without fanfare, without mega-mergers,…
As global science faces mounting complexity, the Paul Scherrer Institute (PSI) stands out as a model of long-term vision, technical excellence, and interdisciplinary ambition. Director Christian Rüegg discusses how PSI…
Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from…
Matthew Brabazon, General Manager of EMEA at SFI Health, a global natural healthcare company, discusses the company’s shift towards branded products and its focus on clinically supported products in the…
We are living in uncertain times. The US government’s rapid-fire retreat from development aid and multilateral participation has shaken up the global system but – as Brendan Shaw argues, reflecting…
With the pharmaceutical landscape growing increasingly complex, few mid-sized players manage to carve out a distinct, resilient path. Rivopharm, a Swiss-headquartered generics manufacturer, is doing just that, expanding its direct…
What if the key to treating chronic and age-related diseases has been hidden in plain sight, within the 98 percent of the human genome once written off as “junk”? HAYA…
Susanne Caspar, CEO of Linnea SA, reflects on five years of growth and transformation at the Swiss botanical extract and API manufacturer. In this interview, Caspar shares insights on navigating…
Patrick Amstutz co-founded Molecular Partners 20 years ago with a vision to revolutionize medicine through protein engineering. Inspired by the potential of DARPins, a novel class of custom-built protein drugs,…
Alentis Therapeutics, under the leadership of its CEO Roberto Iacone, has made significant strides in advancing innovative therapies targeting Claudin-1, a protein critical in inflammation and cancer. The company’s pipeline…
Switzerland has long been recognised as a centre of scientific excellence, and in the field of Advanced Therapy Medicinal Products (ATMPs), it is quickly becoming a regulatory trailblazer. In this…
See our Cookie Privacy Policy Here
